Quantcast

Latest Captain Marvel Stories

2014-09-03 08:32:52

CARLSBAD, Calif., Sept. 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 at 12:50 p.m. ET in New York, NY. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the Company's website,...

2014-07-28 08:28:42

CARLSBAD, Calif., July 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2014 Financial Results and Highlights Conference Call When: Monday, August 4 at 10:30 a.m. ET /7:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above....

2014-07-16 08:27:14

CARLSBAD, Calif., July 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare...

2014-06-24 08:29:49

CARLSBAD, Calif., June 24, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTR(Rx) in patients with familial amyloid polyneuropathy (FAP). http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO ISIS-TTR(Rx) is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and...

2014-06-12 08:28:34

CARLSBAD, Calif., June 12, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2014 Wells Fargo Healthcare Conference at 1:10 p.m. ET and participate in the Gene Manipulation Panel at 2:20 p.m. ET on Tuesday, June 17, 2014 in Boston, MA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentations will be available on the "Investors...

2014-06-11 08:28:25

Event and webcast scheduled on Monday, June 16 at 6:30 a.m. Pacific Time CARLSBAD, Calif., June 11, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Monday, June 16, 2014 at 6:30 a.m. Pacific Time to discuss the ISIS-GCGR(Rx) Phase 2 data presented at the American Diabetes Association's 74(th) Scientific Sessions in San Francisco, CA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO...

2014-06-04 08:30:11

CARLSBAD, Calif., June 4, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 35(th) Annual Global Healthcare Conference on Wednesday, June 11, 2014 at 8:40 a.m. PT in Rancho Palos Verdes, CA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO A live webcast of the presentation will be available on the "Investors & Media" section of the...

2014-06-03 08:31:23

CARLSBAD, Calif., June 3, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2014 Annual Meeting of Stockholders and Open House on Tuesday, June 10 at 2:10 p.m. Pacific Time in Carlsbad, CA. http://photos.prnewswire.com/prnvar/20130807/LA60006LOGO The agenda for the meeting is as follows:2:00 p.m. - 2:10 p.m. Annual Meeting of...

2014-05-20 08:31:54

CARLSBAD, Calif., May 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKK(Rx). ISIS-PKK(Rx) is an antisense drug in development to treat patients with hereditary angioedemia (HAE). HAE is a rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea. HAE affects approximately 20,000 patients in the United...

2014-05-16 08:25:56

CARLSBAD, Calif., May 16, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' R&D Day Presentation When: Thursday, May 22 at 12:00 p.m. ET /9:00 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above. If you are unable to...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related